Skip to main content
. 2022 Jun 27;14(13):3142. doi: 10.3390/cancers14133142

Table 1.

Studies reported on the indoor radon concentration and molecular alterations in NSCLC patients.

Study n Total of Patients Type of
Study
Molecular Alterations Place of Radon Measurement Studied
Area
Radon Median Bq/m3
Exposition
Statistical Significance
Taga et al. [86]
Prospective
2012
n = 70 Case control
study
EGFRm ex19/21 (n = 24) Current
home
Non
radon-prone area
(Moussuri, USA)
EGFRm: 46.5 Bq/m3 Non sig. p = 0.16
Ruano-Raviña et al. [87]
Retrospective
2016
n = 323 Case control
study
(subanalysis of previous study)
EGFRm * (n = 90)
ALKr (n = 12)
Current
home
Radon prone area
(Galicia, Spain)
EGFRm ex19: 216 Bq/m3
EGFRm ex21: 118 Bq/m3
ALKr: 290 Bq/m3
Non sig.
(p value non-available)
Mezquita et al. [88]
Retrospective
2018
n = 116,424 Ecologic
study **
EGFRm (n = 13,125)
ALKr (n = 2928)
BRAFm (n = 2419)
HER2m (n = 816)
ROS1r (n = 373)
KRASm (n = 27,314)
Current
home
Non-radon prone, Intermediate and
radon-prone area
(France)
- p < 0.0001
Mezquita et al. [38]
Prospective
2019
n = 48 Cross-sectional study EGFR m ^ (n = 36)
ALKr (n = 10)
BRAFm (n = 2)
Current
home
Intermediate and
radon-prone area
(Madrid, Spain)
EGFRm: 96 Bq/m3
ALKr: 116 Bq/m3
BRAFm: 125 Bq/m3
Non sig.
p = 0.238
Mezquita et al. [89]
Retrospective
2021
n = 3994 Ecologic
study **
EGFRm (n = 468)
ALKr (n = 129)
BRAFm (n = 89)
HER2m (n = 32)
KRASm (n = 985)
Childhood home Non-radon prone, intermediate and
radon-prone area
(France)
EGFRm: 72.49 Bq/m3
ALKr: 80.24 Bq/m3
BRAFm: 73.22 Bq/m3
HER2m: 72.74 Bq/m3
KRASm: 71.79 Bq/m3
p = 0.0472

Abbreviations: EGFRm, EGFR-mutant; BRAFm, BRAF-mutant; HER2m HER2-mutant; KRASm, KRAS-mutant; ALKr, ALK-rearranged; ROS1r, ROS1-rearranged; ex, exon; Non sig., non-significant; USA, United States of America.* Majority with EGFR exon 19 or 21 mutations; 5 cases were EGFR exon 20 mutations. ^ Including EGFR exon 18, 19 and 21 mutations. ** No radon measurement, estimation of radon exposure according to the National Map (IRSN).